Instituto Valenciano de Oncología (IVO), Valencia, Spain.
Crit Rev Oncol Hematol. 2012 Sep;83(3):341-52. doi: 10.1016/j.critrevonc.2012.01.002. Epub 2012 Jan 29.
Prostate cancer is the most prevalent urogenital malignancy. However, despite initial disease control using androgen deprivation, most of patients eventually develop progressive disease that is resistant to further hormone manipulation. For these patients with castration-resistant prostate cancer (CRPC), and particularly patients with metastatic disease, options have been limited, and prognosis is grim. However, as newer regimens and agents become available, higher rates of objective and biochemical response are being achieved, providing renewed hope for the management of these patients. With the aim of facilitating the treatment of these patients, the Spanish Oncology Genitourinary Group (SOGUG) has issued a series of the recommendations which have been collected in this review. Each recommendation is accompanied by the appropriate level of evidence and grade of recommendation on the basis of the characteristics of the data available.
前列腺癌是最常见的泌尿生殖系统恶性肿瘤。然而，尽管最初使用去势治疗控制了疾病，但大多数患者最终会发展为对进一步激素治疗产生抵抗的进行性疾病。对于这些患有去势抵抗性前列腺癌（CRPC）的患者，特别是患有转移性疾病的患者，选择有限，预后严峻。然而，随着新的治疗方案和药物的出现，客观和生化反应的比率更高，为这些患者的治疗提供了新的希望。为了方便这些患者的治疗，西班牙肿瘤泌尿生殖系统小组（SOGUG）发布了一系列建议，这些建议在本综述中进行了收集。每个建议都附有相应的证据水平和推荐等级，这是基于现有数据的特点。
